UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 16, 2013
PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Maryland | | 001-14494 | | 33-0724736 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | |
10003 Woodloch Forest Drive The Woodlands, TX | | 77380 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (832) 934-1825
__________________________________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
On January 16, 2013, Pernix Therapeutics Holdings, Inc. (“Pernix”) received approval from the NASDAQ Stock Market to transfer its stock listing from NYSE MKT LLC to The NASDAQ Global Market effective with the opening of the market on January 28, 2013. Pernix’s common stock will continue to trade under the symbol “PTX.”
On January 17, 2013, Pernix issued a press release announcing the transfer of its common stock to The NASDAQ Global Market. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated in this Item 8.01 by reference.
| Exhibit Number | | Description |
| | | |
| | Press release by Pernix Therapeutics Holdings, Inc. dated January 17, 2013 |
| | | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | PERNIX THERAPEUTICS HOLDINGS, INC. | |
| | | | |
| Dated: January 17, 2013 | By: | /s/ Cooper C. Collins | |
| | | Cooper C. Collins | |
| | | Chief Executive Officer & President | |
| | | | |
EXHIBIT INDEX
| Exhibit Number | | Description |
| | | |
| | Press release by Pernix Therapeutics Holdings, Inc. dated January 17, 2013 |
| | | |
